Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Food safety diagnostics might feel far from Wall Street, yet Neogen’s supply-chain complexity shows up in hundreds of pages of disclosures. Tracking which genomic test kit drives revenue, or when management sells shares, is difficult. That’s why investors hunting for “Neogen insider trading Form 4 transactions” or the latest “Neogen quarterly earnings report 10-Q filing” often lose hours scrolling through EDGAR.
Stock Titan fixes this. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment it is released, pushes “Neogen Form 4 insider transactions real-time” to your dashboard, and offers “Neogen SEC filings explained simply” with crisp language and data visualizations. Within seconds you’ll see a “Neogen earnings report filing analysis,” flagging segment sales for food safety, animal safety and genomics, plus cash flow shifts tied to acquisitions. Interactive links jump you straight to risk factors, while sidebars answer “understanding Neogen SEC documents with AI” without legalese.
Want specifics? The “Neogen annual report 10-K simplified” highlights R&D spend on LAMP molecular assays and global compliance costs. The “Neogen proxy statement executive compensation” module benchmarks pay packages against peer diagnostics firms. Alerts on “Neogen executive stock transactions Form 4” reveal buying patterns before material announcements, and our dashboard keeps the “Neogen 8-K material events explained” in plain sight when recalls or mergers hit. Whether you compare quarter-over-quarter allergen test kit sales, monitor insider sentiment, or review governance votes, Stock Titan delivers the intelligence you need, updated in real time and ready for decision making.
Nassif Mikheal, identified as CEO and a director of Neogen Corp (NEOG), reported multiple acquisitions on 08/15/2025. He acquired 184,162 shares of common stock and 414,365 shares of common stock at $5.43 per share, leaving 598,527 shares beneficially owned after the transactions. He also acquired derivative rights (options/RSU/PSU grants) exercisable into 1,065,042 and 473,352 shares with an exercise/conversion price of $5.43 and expiration/vesting noted as 08/15/2035. The filing includes vesting schedule notes: some options/RSUs vest over three years, others over four years, and PSUs vest in total at the three-year anniversary. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Gates Capital and related entities report beneficial ownership of 12,793,941 shares of Neogen Corporation common stock, equal to 5.9% of the 217,205,186 shares outstanding as of June 30, 2025. The filing lists Gates Capital Management, L.P.; Gates Capital Management GP, LLC; Gates Capital Management, Inc.; and Jeffrey L. Gates as joint reporting persons, each disclosing shared voting and dispositive power over the same 12,793,941 shares and no sole voting or dispositive power. The statement affirms the shares were acquired in the ordinary course of business and not to influence control of the issuer. The filing includes a joint filing agreement signed August 14, 2025.
A group led by Clarkston Capital Partners, Clarkston Companies and Modell Capital jointly reported beneficial ownership of 14,005,725 shares of Neogen Corporation common stock, representing 6.44% of the company's 217,205,186 outstanding shares used for the calculation. The report breaks ownership down as 5,125,000 shares with sole voting and dispositive power and 8,838,775 (voting) / 8,880,725 (dispositive) shares with shared powers. The filing is presented as a joint Schedule 13G and includes a certification that the securities are held in the ordinary course of business and not with the purpose or effect of changing control.
Neogen Corp. (NEOG) filed its FY-2025 Form 10-K covering the year ended 31 May 2025. The Lansing-based food & animal safety company reports a two-segment structure: Food Safety contributed 71.3 % of FY-25 revenue (vs. 70.9 % FY-24) while Animal Safety supplied 28.7 %. International sales grew to 50.2 % of total. The group employs 2,974 people across 28 countries.
Strategic actions include the April 2025 agreement to divest the global Cleaners & Disinfectants unit and ongoing integration of the 3 M Food Safety Division acquired in Sept 2022 (Reverse Morris Trust). Management still targets cost and revenue synergies but acknowledges impairment charges on the Food Safety reporting unit recorded in Q2 and Q4 FY-25.
Key risk disclosures: (1) Material weaknesses in internal control over financial reporting, mainly ineffective review controls for goodwill valuation; (2) continued challenges merging 3 M’s manufacturing footprint; (3) exposure to tariffs, supply-chain disruption, cybersecurity threats and geopolitical instability; (4) dependence on third-party logistics and single-source suppliers. R&D spend remains at 2-3 % of revenue; no customer represents ≥10 % of sales. Common stock outstanding: 217.2 m shares (30 Jun 2025); public float valued at $2.72 bn (30 Nov 2024).
Norges Bank, manager of Norway’s sovereign wealth fund, filed Amendment No. 3 to Schedule 13G on Neogen Corp (NEOG) as of 30 Jun 2025. The bank now reports beneficial ownership of 9,076,830 common shares, representing 4.2 % of outstanding stock. All shares are held with sole voting and dispositive power; there is no shared power with other parties.
The filing indicates that Norges Bank’s stake has fallen below the 5 % threshold, activating the “Ownership of 5 Percent or Less” disclosure in Item 5. The shares are held on behalf of the Government of Norway and were acquired in the ordinary course of business, with no intent to influence control of the issuer. Aya Sobhy signed the certification on 24 Jul 2025.
Neogen Corp. (NEOG) filed an 8-K disclosing a leadership change. The Board appointed Mikhael Nassif, age 49, as President & CEO effective 11 Aug 2025. Nassif joins from Siemens Healthineers, where he led the global Point-of-Care Diagnostics unit, and previously held senior posts at Baxter, AB InBev, and Johnson & Johnson. The filing states there are no related-party transactions or pre-existing arrangements tied to the appointment.
Compensation package: (1) Base salary $800k, subject to review; (2) Annual bonus target 100% of salary, payout range 0–250%, eligible for the full FY26 cycle; (3) Annual long-term equity grant targeted at $4.5 m; (4) One-time sign-on equity grant of $2 m (50% options, 50% RSUs, 4-year ratable vesting); (5) One-time cash award $500k payable by 5 Sep 2025, repayable if employment ends within one year; (6) Relocation support with full claw-back in year 1 and 50% in year 2; (7) Standard executive severance and benefit programs. A copy of the offer letter is filed as Exhibit 10.1. The company also issued a press release announcing the appointment.
FAQ
What is the current stock price of Neogen (NEOG)?
What is the market cap of Neogen (NEOG)?
